Literature DB >> 16573739

Response to splenectomy is durable after a certain point in time in adult patients with chronic immune thrombocytopenic purpura.

Eva Johansson1, Per Engervall, Ola Landgren, Gunnar Grimfors, Susanne Widell, Shahideh Rezai, Magnus Björkholm.   

Abstract

Splenectomy may lead to a good response in 60-80% of adult patients with corticosteroid refractory idiopathic thrombocytopenic purpura (ITP) but, the long-term response to splenectomy still remains less well defined. We assessed the long-term efficacy and safety of splenectomy in adult patients with chronic ITP. A cohort of 59 splenectomised ITP patients (M/F = 25/34; median age 39 yr; range 14-75) were followed up for a median of 18 yr (range 2-32). No life-threatening surgical complications were observed. The overall response rate was 78% with 59% complete remission (CR) and 19% partial remission (PR). CR and PR patients were younger than non-responding patients at time of diagnosis (median age: 36 yr vs 48 yr, P = 0.03) and at splenectomy (median age: 38 yr vs 51 yr, P = 0.02). Among the 46 responding patients, eventually 17 had relapse. No disease progression occurred after 12.1 and 7.3 yr for patients in CR or PR, respectively. One case of fatal septicaemia was recorded. We conclude that splenectomy is an effective and safe treatment in adult patients with chronic ITP failing to respond to corticosteroid treatment and importantly, our findings support the view that response to splenectomy is durable after a certain point in time.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16573739     DOI: 10.1111/j.1600-0609.2006.00665.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  5 in total

1.  Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years.

Authors:  Nicola Vianelli; Francesca Palandri; Nicola Polverelli; Roberto Stasi; Joel Joelsson; Eva Johansson; Marco Ruggeri; Francesco Zaja; Silvia Cantoni; Angelo Emanuele Catucci; Anna Candoni; Enrica Morra; Magnus Björkholm; Michele Baccarani; Francesco Rodeghiero
Journal:  Haematologica       Date:  2012-11-09       Impact factor: 9.941

2.  Long-term outcomes of a 5-year follow up of patients with immune thrombocytopenic purpura after splenectomy.

Authors:  Jae Joon Han; Sun Kyung Baek; Jae Jin Lee; Si-Young Kim; Kyung Sam Cho; Hwi-Joong Yoon
Journal:  Korean J Hematol       Date:  2010-09-30

3.  Prediction of response to splenectomy in patients with idiopathic thrombocytopenic purpura.

Authors:  A Shojaiefard; S A Mousavi; S H Faghihi; S Abdollahzade
Journal:  World J Surg       Date:  2008-03       Impact factor: 3.352

4.  Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting.

Authors:  Lauren C Bylsma; Jon P Fryzek; Karynsa Cetin; Fiona Callaghan; Carla Bezold; Bhakti Mehta; Jeffrey S Wasser
Journal:  Am J Hematol       Date:  2018-10-21       Impact factor: 10.047

Review 5.  Current Management of Primary Immune Thrombocytopenia.

Authors:  Drew Provan; Adrian C Newland
Journal:  Adv Ther       Date:  2015-10-26       Impact factor: 3.845

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.